Amundi Sells 698,283 Shares of Qiagen N.V. $QGEN

Key Points

• Amundi reduced its holdings in Qiagen N.V. by 13.8% during the first quarter, selling 698,283 shares and owning approximately 1.96% of the company at a value of $175.76 million.
• Equities analysts have diverse opinions on Qiagen, with three analysts rating it as a Buy and eight giving it a Hold rating; the current consensus price target is $49.69.
• Qiagen reported earnings of $0.60 EPS for the quarter, matching expectations, with revenues of $533.54 million, reflecting a 7.7% increase year over year.

Amundi decreased its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 13.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,353,734 shares of the company's stock after selling 698,283 shares during the quarter. Amundi owned approximately 1.96% of Qiagen worth $175,760,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in Qiagen by 3,030.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock worth $179,501,000 after purchasing an additional 4,327,934 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Qiagen by 12.2% in the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock valued at $972,191,000 after acquiring an additional 2,656,136 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Qiagen in the fourth quarter worth about $95,746,000. Deutsche Bank AG raised its position in Qiagen by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Qiagen in the first quarter worth about $44,078,000. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Down 1.1%

Shares of Qiagen stock traded down $0.51 during trading hours on Wednesday, reaching $46.53. 157,083 shares of the company's stock were exchanged, compared to its average volume of 1,379,922. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The stock has a market cap of $10.34 billion, a P/E ratio of 27.50, a P/E/G ratio of 2.51 and a beta of 0.64. The company has a 50 day moving average of $48.62 and a two-hundred day moving average of $44.50. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same period in the previous year, the firm earned $0.55 EPS. The company's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. UBS Group increased their price target on Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Wall Street Zen downgraded Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Barclays started coverage on Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Finally, Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.